Tower Research Capital LLC TRC lifted its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 53.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 149,644 shares of the company's stock after buying an additional 51,903 shares during the period. Tower Research Capital LLC TRC's holdings in Kenvue were worth $3,195,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in KVUE. Transatlantique Private Wealth LLC boosted its position in Kenvue by 5.7% in the fourth quarter. Transatlantique Private Wealth LLC now owns 10,680 shares of the company's stock valued at $228,000 after buying an additional 580 shares during the last quarter. Trajan Wealth LLC lifted its stake in Kenvue by 10.7% during the 4th quarter. Trajan Wealth LLC now owns 204,966 shares of the company's stock valued at $4,376,000 after acquiring an additional 19,797 shares during the period. Mirabella Financial Services LLP purchased a new stake in shares of Kenvue in the 4th quarter valued at $778,000. MML Investors Services LLC increased its stake in shares of Kenvue by 528.3% in the fourth quarter. MML Investors Services LLC now owns 1,125,552 shares of the company's stock worth $24,031,000 after acquiring an additional 946,422 shares during the period. Finally, MetLife Investment Management LLC raised its holdings in shares of Kenvue by 1.9% during the fourth quarter. MetLife Investment Management LLC now owns 507,418 shares of the company's stock worth $10,833,000 after purchasing an additional 9,431 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on KVUE. Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Citigroup upped their price objective on Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a research report on Monday, April 14th. UBS Group cut their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Finally, Redburn Atlantic began coverage on shares of Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of "Hold" and a consensus target price of $24.42.
Read Our Latest Report on KVUE
Kenvue Price Performance
Shares of KVUE stock traded up $0.28 on Friday, reaching $23.03. 22,249,585 shares of the company were exchanged, compared to its average volume of 17,101,629. The company has a market cap of $44.19 billion, a price-to-earnings ratio of 43.45, a P/E/G ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The business has a 50-day moving average price of $23.01 and a 200 day moving average price of $22.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.
Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.56%. Kenvue's payout ratio is currently 154.72%.
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
